AXFOY
Q4 2026 EPS Estimate
$0.37
Oct 22, 2026
Revenue Estimate
$2.38B
FY2026E EPS$11.76
FY2027E EPS$13.10

No analyst ratings available

No analyst price targets available for AXFOY

Analyst coverage may not be available for this symbol

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+4.18%
EPS+11.38%
FY2028
Rev+3.93%
EPS+6.62%
FY2029
Rev+3.83%
EPS+3.30%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$91.59B$95.42B$99.17B$102.97B$104.66B
Low$91.16B$94.39B$98.39B$102.16B$103.84B
High$91.98B$96.99B$100.20B$104.04B$105.75B
EBITDA Avg$7.53B$7.85B$8.16B$8.47B$8.61B
Low$7.50B$7.76B$8.09B$8.40B$8.54B
High$7.56B$7.98B$8.24B$8.56B$8.70B
EBIT Avg$3.88B$4.04B$4.20B$4.36B$4.43B
Low$3.86B$4.00B$4.17B$4.33B$4.40B
High$3.90B$4.11B$4.25B$4.41B$4.48B
Net Income Avg$2.55B$2.84B$3.03B$3.13B$3.19B
Low$2.52B$2.81B$3.00B$3.10B$3.16B
High$2.58B$2.88B$3.07B$3.17B$3.23B
EPS Avg$11.76$13.10$13.97$14.43$14.71
Low$11.64$12.97$13.82$14.28$14.56
High$11.92$13.28$14.16$14.62$14.91
Analysts (Rev / EPS)7 / 17 / 13 / 13 / 15 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$22.94B$23.81B$22.67B$25.23B$24.45B$25.35B
Low$22.86B$23.49B$22.47B$25.01B$24.24B$25.13B
High$23.05B$24.00B$22.81B$25.38B$24.60B$25.51B
EBITDA Avg$1.89B$1.96B$1.86B$2.07B$2.01B$2.08B
Low$1.88B$1.93B$1.85B$2.06B$1.99B$2.07B
High$1.90B$1.97B$1.88B$2.09B$2.02B$2.10B
EBIT Avg$972M$1.01B$960M$1.07B$1.04B$1.07B
Low$969M$995M$952M$1.06B$1.03B$1.06B
High$977M$1.02B$966M$1.08B$1.04B$1.08B
Net Income Avg$769M$625M$636M$832M$954M$795M
Low$760M$618M$629M$823M$943M$786M
High$775M$630M$641M$839M$961M$801M
EPS Avg$3.55$2.88$2.93$3.84$4.40$3.67
Low$3.51$2.85$2.90$3.79$4.35$3.63
High$3.58$2.91$2.96$3.87$4.43$3.70
Analysts (Rev / EPS)4 / 13 / 11 / 11 / 11 / 11 / 1

Earnings Surprises

Recent Analyst Actions

No recent analyst actions

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.